



1 **Supplementary Figure 1.**

2


3 **A**



B



1 **Supplementary Figure 2.**




2

3 (A) Gating strategies for IL-17⁺ producing T cells and Treg cells. (B) Percentage of CD8⁺ T cells
4 (CD3⁺CD4⁻CD8⁺) in the spleen at 15 weeks of age (n≥6 per group). (C) Percentage of IL-17
5 producing cells in splenic DN-T cells at 15 weeks of age (n≥6 per group). (D) Level of IL-35 in
6 the mouse serum at 15 weeks of age (n≥6 per group). **p< 0.01, n.s.: not statistically significant.

7


1 **Supplementary Figure 3**



10 (A) Relative abundance of Verrucomicrobia in fecal microbiota (n=12 per group). (B) Percentage
 11 of *L. animalis* in Lactobacillales in the feces of mice at different ages with or without vancomycin
 12 treatment (n≥10 per group). (C) Relative abundance of Bacteroidales, Acholeplasmatales,
 13 Verrucomicrobiales and Desulfovibrionales in fecal microbiota at different ages (n=12 per
 14 group). * $p<0.05$, ** $p<0.01$, *** $p<0.001$, n.s.: not statistically significant.

15

1 **Supplementary Figure 4**



2

3 (A) Level of anti-LPS and anti-flagellin IgG in the plasma of human lupus patients and healthy
4 controls ($n \geq 5$ per group). (B) Correlation analysis of human anti-LPS IgG and anti-flagellin IgG.
5 (C) Level of anti-LPS and anti-flagellin IgG in the mouse serum. Ipr-F-old: female MRL/lpr mice
6 at 15 weeks of age. Ipr-F-young: female MRL/lpr mice at 7 weeks of age. MRL-F-old: female
7 MRL mice at 15 weeks of age ($n \geq 7$ per group). (D) Correlation analysis of mouse anti-LPS IgG
8 and anti-flagellin IgG. (E) Level of anti-LPS IgG in mouse serum at 15 weeks of age ($n \geq 6$ per
9 group). (F) Level of anti-LPS IgG in mouse serum at 15 weeks of age ($n \geq 7$ per group). * $p < 0.05$,
10 ** $p < 0.01$, n.s.: not statistically significant.